Correlation of LAPTM4B polymorphisms with cervical carcinoma
Fanling Meng1, Hongtao Song, Chang Luo
1Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
Cancer
|June 10, 2011
Summary
The LAPTM4B*2 allele is linked to an increased risk of cervical cancer, particularly in younger, smoking, premenopausal women. This finding suggests LAPTM4B may be a significant genetic factor in cervical cancer development.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Lysosome-associated protein transmembrane 4 beta (LAPTM4B) is an oncoprotein overexpressed in various carcinomas.
- LAPTM4B genetic variations (polymorphisms) are associated with cancer risk.
Purpose of the Study:
- To investigate the association between LAPTM4B alleles and cervical cancer risk.
- To determine if specific LAPTM4B genotypes increase susceptibility to cervical cancer.
Main Methods:
- Case-control study involving 317 cervical cancer patients and 416 controls.
- Genomic DNA analysis using polymerase chain reaction to determine LAPTM4B genotypes.
- Logistic regression analysis to calculate odds ratios and confidence intervals.
Main Results:
- A higher frequency of the LAPTM4B*2 allele was observed in cervical cancer cases (35.8%) compared to controls (26.3%).
- Carrying LAPTM4B*1/2 or *2/2 genotypes significantly increased cervical cancer risk (ORs 1.60 and 2.12, respectively).
- Increased risk was more pronounced in younger individuals, smokers, premenopausal women, and those with higher parity; joint effects with smoking were noted.
Conclusions:
- The LAPTM4B*2 allele is a potential risk factor for cervical cancer.
- LAPTM4B genetic variations may contribute to susceptibility to cervical cancer in the Chinese population.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
03:18Non-LTR Retrotransposons
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...